Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.
Tobudic S, Plunger V, et al.PLoS ONE [Electronic Resource] 2012; 7(9): e46133.
Aims
To determine the immunogenicity of a prime–boost vaccination strategy using 7-valent pneumococcal conjugate vaccine (7vPnC) followed by pneumococcal polysaccharide vaccine (PPV) 12 months later.
Interventions
7vPnC (0.5 ml) versus PPV (0.5 ml) for primary pneumococcal vaccination. All patients received PPV vaccination one year later.
Participants
80 adult renal transplant recipients who were at least 6 months posttransplant.
Outcomes
Primary endpoint was vaccine response of the primed group (7vPnC/PPV) compared with single PPV vaccination. Secondary endpoints were vaccine response after the primed 7vPnC/PPV regime compared with sequential PPV/PPV vaccination, decline of antibody response/vaccine response 1 year after 7vPnC or PPV vaccination, and tolerability of vaccine regimes.
Follow-up
1 year
CET Conclusions
In this good quality study in adult renal transplant recipients immunosuppression with a 7-valent pneumococcal conjugate vaccine (7vPnC) followed by a booster at 1 year with 23-valent pneumococcal polysaccharide vaccine (PPV) was not superior to a single PPV vaccination. Thus a single dose of PPV should continue to be regarded as the standard or care.
Data analysis
Modified intention-to-treat analysis
Trial registration
EudraCT 2007-004590-25.